# Fertility preservation and assisted reproductive strategies in endometrial cancer patients with lynch syndrome

**Authors:** Junhan Liu, Ying Zheng, Jianhong Liu

PMC · DOI: 10.3389/fonc.2025.1630301 · Frontiers in Oncology · 2025-07-21

## TL;DR

Endometrial cancer patients with Lynch syndrome can use fertility-sparing treatments and assisted reproduction with genetic testing to safely have children.

## Contribution

The study highlights the importance of early ART and PGT-M in minimizing hereditary risks and improving reproductive outcomes for LS-EC patients.

## Key findings

- Early initiation of ART, especially IVF with FET, improves reproductive outcomes in LS-EC patients.
- PGT-M effectively prevents the transmission of pathogenic MMR variants to offspring.
- Radical surgery is recommended after childbearing to reduce cancer recurrence.

## Abstract

Patients with LS-EC can be treated with progestin-based fertility-sparing treatment under close monitoring, and pregnancy is recommended as soon as possible after complete remission (CR) of the disease, with assisted reproduction, supplemented by PGT-M, to minimize the probability of inheritance of the disease in the offspring. Radical surgery for endometrial cancer is recommended as soon as possible after completion of childbearing to minimize recurrence. The role of assisted reproductive technologies (ART) and preimplantation genetic testing for monogenic disorders (PGT-M) was explored. For patients achieving CR, early initiation of ART, especially IVF with frozen-thawed embryo transfer (FET), was associated with improved reproductive outcomes. PGT-M proved valuable in preventing the transmission of pathogenic MMR variants to offspring. Early use of ART and integration of PGT-M are critical for maximizing reproductive success while minimizing oncologic and hereditary risks.

## Linked entities

- **Diseases:** endometrial cancer (MONDO:0002447), Lynch syndrome (MONDO:0005835)

## Full-text entities

- **Genes:** MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}, MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}
- **Diseases:** CR (MESH:D012075), HNPCC (MESH:D015179), IVF (MESH:C566179), monogenic disorders (MESH:D009358), endometrial lesions (MESH:D014591), cancer (MESH:D009369), hyperplasia (MESH:D006965), EC (MESH:D016889), bleeding (MESH:D006470), MMR-D (MESH:C536928), hereditary cancer syndromes (MESH:D009386), colorectal, endometrial, or ovarian cancer (MESH:D018203), deficiency (MESH:D007153), metastasis (MESH:D009362), EEC (MESH:D018269), associated (MESH:D018886), anxiety (MESH:D001007), LS (MESH:D007888), Lynch syndrome (MESH:D003123), -D (MESH:D014808), obese (MESH:D009765), M (MESH:C566367), PGT-M (MESH:D013736), primary infertility (MESH:D007246), autosomal dominant disorder (MESH:D030342)
- **Chemicals:** GnRH-a (-), letrozole (MESH:D000077289), dostarlimab (MESH:C000719628), pembrolizumab (MESH:C582435), LNG (MESH:D016912)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.3261dupC

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12318751/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12318751/full.md

---
Source: https://tomesphere.com/paper/PMC12318751